Table 2 Hazard ratios associated with sNfL and other risk factors.

From: Serum neurofilament indicates accelerated neurodegeneration and predicts mortality in late-stage Parkinson’s disease

Characteristic

HR

95% CI

p value

log(NfL) (1 point increase)

13.9

4.93, 39.3

<0.001

sNfL > 26.9 pg/ml

13.6

3.53, 52.3

<0.001

≥1 milestone

5.04

0.62, 40.9

0.13

≥2 milestones

21.0

2.67, 166

0.004

Number of milestones (increase by 1)

3.86

2.22, 6.72

<0.001

Milestone dementia

11.6

2.55, 52.6

0.002

Milestone visual hallucinations

5.53

1.97, 15.6

0.001

Milestone nursing home admission

4.58

1.61, 13.0

0.004

Milestone recurrent falls

4.55

0.99, 20.9

0.051

MoCA (1 point decrease)

1.21

1.14, 1.29

<0.001

UPDRS III (1 point increase)

1.09

1.04, 1.14

<0.001

Hoehn & Yahr (1 point increase)

2.80

1.65, 4.74

<0.001

  1. Hazard ratios were obtained from multiple Cox-regression models predicting death in the observation period adjusted for age at baseline, disease duration and sex. One point increase in log(NfL) corresponds to a 2.718-fold increase of sNfL. CI confidence interval, HR hazard ratio, MoCA Montreal Cognitive Assessment, sNfL serum neurofilament light chain, UPDRS III Unified Parkinson’s Disease Rating Scale Part III. p values of significant Hazard Ratios are marked in bold.
Back to article page